Akinchan Bhardwaj: Differences in Bleeding Outcomes Among DOACs
Akinchan Bhardwaj, Consultant Interventional Cardiologist at Kauvery Hospital, shared a post on LinkedIn about a recent article by Lana A. Castellucci published in NEJM, adding:
“Two of the most commonly used anticoagulants in the world… but are they really equivalent?
For years, clinicians have treated apixaban and rivaroxaban as largely interchangeable for venous thromboembolism.
A new randomized trial published in NEJM challenges that assumption.
In the COBRRA trial, more than 2700 patients with acute VTE were randomized to apixaban or rivaroxaban. Striking results!
Clinically relevant bleeding
- Apixaban: 3.3%
- Rivaroxaban: 7.1%
That is about a 54% relative reduction in bleeding risk.
Importantly, this difference appeared within the first 3 months, the highest-risk phase of anticoagulation therapy.
Why this matters clinically?
- Anticoagulation decisions are rarely about efficacy alone.
- They are about balancing thrombosis prevention with bleeding risk.
- If two agents prevent clots similarly but one carries substantially less bleeding, that changes real-world prescribing decisions.
For clinicians managing:
- Pulmonary embolism
- Proximal DVT
- Early anticoagulation after diagnosis
These data may influence which DOAC becomes the default choice.
Bigger picture:
We often assume drugs within the same class behave the same.
But trial-level comparisons show us that pharmacology still matters.
Small differences in mechanism, dosing schedules, and pharmacokinetics can translate into meaningful differences for patients.
Curious how others are thinking about this.
Would this change your first-line DOAC choice in acute VTE?”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Read the Full Article on NEJM
More posts featuring Akinchan Bhardwaj on Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers